A. P. Otmakhov
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
A. P. Otmakhov has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- A.A. Salnikov
Noyabrsk Psychoneurological Dispensary
2 shared publications - Georgy Yu. Selivanov
Mental Health Research Institute — Tomsk National Research Medical Center Russian Academy of Sciences
2 shared publications - K. A. Blonsky
Nizhnevartovsk Psychoneurological Hospital
2 shared publications - Nikolay Aleksandrovich Bokhan
Mental Health Research Institute — Tomsk National Research Medical Center Russian Academy of Sciences
2 shared publications - A. P. Otmakhov
Almazov National Medical Research Centre
1 shared publication - B.G. Rebzuev
Herzen State Pedagogical University of Russia
1 shared publication
Latest Publications
- 20 October 2026
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 126 (9) , 114-122
Efficacy and tolerability of co-administration of clozapine with atypical antipsychotics in patients with treatment-resistant schizophrenia, comorbid with chemical addictions
Objective. To compare the efficacy and tolerability of combination therapy with clozapine and atypical antipsychotics for patients with treatment-resistant schizophrenia, comorbid with chemical addictions. Material and methods. A clinical study was conducted from 2018 to 2026 in various psychiatric departments in the North-Western, Siberian, and Ural regions of the Russian Federation. The study included a total of 470 male and female participants diagnosed with therapeutically resistant paranoid schizophrenia, comprising individuals with and without concomitant chemical addictions: n=80 without addictions; n=390 with unrelated chemical addictions (opioid, cannabinoid, psychostimulant, and ethanol dependence). Participants were randomly allocated into six treatment groups receiving distinct combinations of medications: clozapine with cariprazine (n=84), lurasidone (n=84), aripiprazole (n=78), risperidone (n=84), olanzapine (n=70), or brexpiprazole (n=70). The clinical status of patients was assessed at weeks 2 and 6 of the therapeutic regimen. Results. A comparative analysis of treatment efficacy indicated significant differences between therapy groups across various psychometric scales (p<0.05). The co-administration of clozapine with cariprazine, and to a lesser extent with lurasidone, demonstrated the most pronounced therapeutic effect within a 42-day treatment period (p<0.05), specifically in alleviating psychotic symptoms and reducing the negative symptoms characteristic of schizophrenia, as compared to alternative combinations, thereby extending the duration of outpatient treatment. Conclusions. A comprehensive treatment strategy for therapeutically resistant schizophrenia, irrespective of concomitant addictions, is the combination of clozapine with cariprazine; lurasidone serves as an alternative option. The selection of an effective adjunctive therapy should consider the specific type of addiction: lurasidone or aripiprazole is recommended for cannabinoid, psychostimulant, and alcohol dependencies; risperidone or olanzapine is advised for opioid and alcohol dependencies. The combination with brexpiprazole is deemed ineffective. Notable advantages of this approach include a marked effect on negative symptoms and an extension of the outpatient treatment period. No adverse events associated with the combination therapy were reported.
- 20 October 2026
- Published by Media Sphere Publishing Group in S.S. Korsakov Journal of Neurology and Psychiatry
- Vol. 126 (9) , 114-122
Efficacy and tolerability of co-administration of clozapine with atypical antipsychotics in patients with treatment-resistant schizophrenia, comorbid with chemical addictions
Objective. To compare the efficacy and tolerability of combination therapy with clozapine and atypical antipsychotics for patients with treatment-resistant schizophrenia, comorbid with chemical addictions. Material and methods. A clinical study was conducted from 2018 to 2026 in various psychiatric departments in the North-Western, Siberian, and Ural regions of the Russian Federation. The study included a total of 470 male and female participants diagnosed with therapeutically resistant paranoid schizophrenia, comprising individuals with and without concomitant chemical addictions: n=80 without addictions; n=390 with unrelated chemical addictions (opioid, cannabinoid, psychostimulant, and ethanol dependence). Participants were randomly allocated into six treatment groups receiving distinct combinations of medications: clozapine with cariprazine (n=84), lurasidone (n=84), aripiprazole (n=78), risperidone (n=84), olanzapine (n=70), or brexpiprazole (n=70). The clinical status of patients was assessed at weeks 2 and 6 of the therapeutic regimen. Results. A comparative analysis of treatment efficacy indicated significant differences between therapy groups across various psychometric scales (p<0.05). The co-administration of clozapine with cariprazine, and to a lesser extent with lurasidone, demonstrated the most pronounced therapeutic effect within a 42-day treatment period (p<0.05), specifically in alleviating psychotic symptoms and reducing the negative symptoms characteristic of schizophrenia, as compared to alternative combinations, thereby extending the duration of outpatient treatment. Conclusions. A comprehensive treatment strategy for therapeutically resistant schizophrenia, irrespective of concomitant addictions, is the combination of clozapine with cariprazine; lurasidone serves as an alternative option. The selection of an effective adjunctive therapy should consider the specific type of addiction: lurasidone or aripiprazole is recommended for cannabinoid, psychostimulant, and alcohol dependencies; risperidone or olanzapine is advised for opioid and alcohol dependencies. The combination with brexpiprazole is deemed ineffective. Notable advantages of this approach include a marked effect on negative symptoms and an extension of the outpatient treatment period. No adverse events associated with the combination therapy were reported.
- Open Access
- 9 November 2024
- Published by Medical Informational Agency Publishers in Psychiatry (Moscow) (Psikhiatriya)
- Vol. 22 (4) , 115-128
Cariprazine in Hospital Treatment of Acute Psychotic Conditions Due to Comorbid Schizophrenia and Chemical Addictions
Background: endogenous psychoses complicated with different addictions have special psychopathological structure including delirious episodes, true hallucinations combined with typical positive symptoms of schizophrenia. These cases are difficult for treatment due to non-compliance of patients and their bad tolerance to drugs. The aim was to study the most effective psychopharmacological treatment using cariprazine for acute psychotic states in paranoid schizophrenia combined with chemical addictions. Patients and Methods: the study was conducted at psychiatric hospitals of Tomsk region, St. Petersburg, Nizhnevartovsk and Noyabrsk from 2018 to 2024. 208 men aged 18 to 45 years suffering from paranoid schizophrenia and dependent on psychoactive substances were examined. The main group made up 104 in-patients, who took cariprazine alone or in combination with haloperidol or chlorpromazine. The control group included 104 in-patients treated with other antipsychotics (aripiprazole, risperidone, olanzapine). Research methods: clinical and psychopathological, psychometric (PANSS, SANS, CGI, GAF), statistical (Python 3.11.0; R version 3.2.4; SPSS Statistics Base 22.0). Results: It was revealed that when comparing the control group with the main group, similar indicators were observed on the CGI and GAF scales on the 2nd week of the study, and on the 4th week of the study, compared with the control group, an improvement in indicators on the PANSS, SANS, CGI, GAF scales was observed. Conclusions: Cariprazine, compared with other atypical antipsychotics (risperidone, olanzapine, aripiprazole), showed a distinct antipsychotic effect in the treatment of acute psychotic states in patients with schizophrenia dependent on psychoactive substances. By the end of the 2nd week after hospitalization, when treating with cariprazine at an average dose of 3 to 6 mg/day in combination with typical neuroleptics (haloperidol, chlorpromazine) or a tranquilizer, the most pronounced antipsychotic effect is achieved. Subsequent isolated use of cariprazine at a therapeutic dose of 3–4.5 mg/day has an effect similar to that of leading atypical antipsychotics by the end of the 4th week of treatment. Unlike other atypical antipsychotics, cariprazine was more effective in the treatment of negative symptoms of schizophrenia, which made it possible to achieve an improvement in overall functioning, increase the duration of remission, and reduce the risk of rehospitalization and the development of hospitalism.
- 9 November 2024
- Published by Medical Informational Agency Publishers in Psychiatry (Moscow) (Psikhiatriya)
- Vol. 22 (4) , 115-128
Open AccessCariprazine in Hospital Treatment of Acute Psychotic Conditions Due to Comorbid Schizophrenia and Chemical Addictions
Background: endogenous psychoses complicated with different addictions have special psychopathological structure including delirious episodes, true hallucinations combined with typical positive symptoms of schizophrenia. These cases are difficult for treatment due to non-compliance of patients and their bad tolerance to drugs. The aim was to study the most effective psychopharmacological treatment using cariprazine for acute psychotic states in paranoid schizophrenia combined with chemical addictions. Patients and Methods: the study was conducted at psychiatric hospitals of Tomsk region, St. Petersburg, Nizhnevartovsk and Noyabrsk from 2018 to 2024. 208 men aged 18 to 45 years suffering from paranoid schizophrenia and dependent on psychoactive substances were examined. The main group made up 104 in-patients, who took cariprazine alone or in combination with haloperidol or chlorpromazine. The control group included 104 in-patients treated with other antipsychotics (aripiprazole, risperidone, olanzapine). Research methods: clinical and psychopathological, psychometric (PANSS, SANS, CGI, GAF), statistical (Python 3.11.0; R version 3.2.4; SPSS Statistics Base 22.0). Results: It was revealed that when comparing the control group with the main group, similar indicators were observed on the CGI and GAF scales on the 2nd week of the study, and on the 4th week of the study, compared with the control group, an improvement in indicators on the PANSS, SANS, CGI, GAF scales was observed. Conclusions: Cariprazine, compared with other atypical antipsychotics (risperidone, olanzapine, aripiprazole), showed a distinct antipsychotic effect in the treatment of acute psychotic states in patients with schizophrenia dependent on psychoactive substances. By the end of the 2nd week after hospitalization, when treating with cariprazine at an average dose of 3 to 6 mg/day in combination with typical neuroleptics (haloperidol, chlorpromazine) or a tranquilizer, the most pronounced antipsychotic effect is achieved. Subsequent isolated use of cariprazine at a therapeutic dose of 3–4.5 mg/day has an effect similar to that of leading atypical antipsychotics by the end of the 4th week of treatment. Unlike other atypical antipsychotics, cariprazine was more effective in the treatment of negative symptoms of schizophrenia, which made it possible to achieve an improvement in overall functioning, increase the duration of remission, and reduce the risk of rehospitalization and the development of hospitalism.
- Open Access
- 15 August 2023
- Published by Moscow State University of Psychology and Education in Experimental Psychology (Russia)
- Vol. 16 (2) , 157-177
Role of Causal Attribution and State Self-Esteem in Emergence of Brand Commitment
Based on the analysis of Kisler's commitment model and Weiner's attribution theory, a hypothetical chain of events resulting in brand commitment was offered: focus of attention → causal dimension → self-esteem → commitment. Its existence was tested in two studies that manipulated the focus of attention of participants in order to strengthen the weight of one of the two causal dimensions, attribution of choice results to internal/external causes (Experiment 1) and attribution of choice results to stable/unstable causes (Experiment 2). 60 students (29 men) and 72 students (29 men), respectively participated in studies. Results were analyzed using ANOVA and path analysis and supported the existence of the assumed chain of events resulting in commitment in both studies. At the same time, as expected, such a chain of events was more pronounced in the situation of success in Experiment 1 and in the situation of failure in Experiment 2. The advantages of using the attribution theory to explain the commitment and prospects for further research in this area are discussed.
- 15 August 2023
- Published by Moscow State University of Psychology and Education in Experimental Psychology (Russia)
- Vol. 16 (2) , 157-177
Open AccessRole of Causal Attribution and State Self-Esteem in Emergence of Brand Commitment
Based on the analysis of Kisler's commitment model and Weiner's attribution theory, a hypothetical chain of events resulting in brand commitment was offered: focus of attention → causal dimension → self-esteem → commitment. Its existence was tested in two studies that manipulated the focus of attention of participants in order to strengthen the weight of one of the two causal dimensions, attribution of choice results to internal/external causes (Experiment 1) and attribution of choice results to stable/unstable causes (Experiment 2). 60 students (29 men) and 72 students (29 men), respectively participated in studies. Results were analyzed using ANOVA and path analysis and supported the existence of the assumed chain of events resulting in commitment in both studies. At the same time, as expected, such a chain of events was more pronounced in the situation of success in Experiment 1 and in the situation of failure in Experiment 2. The advantages of using the attribution theory to explain the commitment and prospects for further research in this area are discussed.
- Open Access
- 29 September 2022
- Published by Medical Informational Agency Publishers in Psychiatry (Moscow) (Psikhiatriya)
- Vol. 20 (3) , 124-133
Features of Psychosocial Functioning of Patients with Bipolar Affective Disorder: Modern Methods of Patients’ Rehabilitation
Introduction: bipolar affective disorder frequently presents residual symptoms even in interictal period, what in its turn causes problems in psychosocial functioning, cognitive impairment and poor quality of life. Nowadays, the treatment targets are focused not only on clinical remission, but also on functional recovery and in personal recovery, patients’ quality of life. Scientific review contains results of researches, aimed on therapy modalities, that can be effective in decreasing maladjustment, integration into society, prevention of social and labour deadaptation.Purpose: to present an analysis of scientific data on currently existing approaches to the restoration of the psychosocial functioning of patients suffering from bipolar disorder and evaluate their effectiveness.Materials and methods: the keywords “bipolar affective disorder”, “psychosocial intervention”, “cognitive-behavioral therapy”, “psychoeducation” were used to search scientific articles in the databases PubMed, еLibrary.Conclusion: with a view to rehabilitation were used such modalities as psychoeducation, cognitive-behavioral therapy, family focused therapy. The question remains whether of these interventions are effective and should be integrated into treatment regimen of bipolar affective disorder.
- 29 September 2022
- Published by Medical Informational Agency Publishers in Psychiatry (Moscow) (Psikhiatriya)
- Vol. 20 (3) , 124-133
Open AccessFeatures of Psychosocial Functioning of Patients with Bipolar Affective Disorder: Modern Methods of Patients’ Rehabilitation
Introduction: bipolar affective disorder frequently presents residual symptoms even in interictal period, what in its turn causes problems in psychosocial functioning, cognitive impairment and poor quality of life. Nowadays, the treatment targets are focused not only on clinical remission, but also on functional recovery and in personal recovery, patients’ quality of life. Scientific review contains results of researches, aimed on therapy modalities, that can be effective in decreasing maladjustment, integration into society, prevention of social and labour deadaptation.Purpose: to present an analysis of scientific data on currently existing approaches to the restoration of the psychosocial functioning of patients suffering from bipolar disorder and evaluate their effectiveness.Materials and methods: the keywords “bipolar affective disorder”, “psychosocial intervention”, “cognitive-behavioral therapy”, “psychoeducation” were used to search scientific articles in the databases PubMed, еLibrary.Conclusion: with a view to rehabilitation were used such modalities as psychoeducation, cognitive-behavioral therapy, family focused therapy. The question remains whether of these interventions are effective and should be integrated into treatment regimen of bipolar affective disorder.